Evidence map›Paper›PMID 37156634›Full record

Trial reportNicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco2023

A Secondary Analysis of a Preliminary Contingency Management Intervention for Presurgical Cancer Patients: Evaluating Individual Participant Data.

Brandon T Sanford, Benjamin A Toll, Lisa M Fucito, Nathaniel L Baker, Suchitra Krishnan-Sarin, Matthew J Carpenter, Steven L Bernstein, Alana M Rojewski

Open access · bronzeAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 50% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Brandon T SanfordDepartment of Public Health Sciences, Medical University of South Carolina, Charleston, SC, USA.
Benjamin A TollDepartment of Public Health Sciences, Medical University of South Carolina, Charleston, SC, USA.ORCID 0000-0001-7978-8416
Lisa M FucitoYale School of Medicine, Yale University, New Haven, CT, USA.
Nathaniel L BakerDepartment of Public Health Sciences, Medical University of South Carolina, Charleston, SC, USA.ORCID 0000-0003-3313-1579
Suchitra Krishnan-SarinYale School of Medicine, Yale University, New Haven, CT, USA.
Matthew J CarpenterDepartment of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, SC, USA.
Steven L BernsteinGeisel School of Medicine, Dartmouth-Hitchcock Medical Center, Hanover, NH, USA.ORCID 0000-0002-9964-7036
Alana M RojewskiDepartment of Public Health Sciences, Medical University of South Carolina, Charleston, SC, USA.ORCID 0000-0003-1531-9287
Medical University of South Carolina · USYale University · USDartmouth–Hitchcock Medical Center · US

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
Pulmonary Focused Foundations in Innovation and Scholarship (PuFFInS)T32HL144470 · NHLBI · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI Carol A. Feghali-Bostwick · 2019 to 2026
$2.6M
Genetic testing, treatment use, and mortality after diagnosis of breast and ovarian cancer: The Georgia-California GeneLINK InitiativeR01CA225697 · NCI · STANFORD UNIVERSITY · PI KATZ, STEVEN J., KURIAN, ALLISON W. · 2018 to 2021
$1.6M
Scleroderma Twin Study and analysis of Estrogen in patients with dcSScK24AR060297 · NIAMS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI FEGHALI-BOSTWICK, CAROL A. · 2013 to 2025
$1.4M
Tobacco Treatment in the Context of Lung Cancer Screening - Administrative SupplementK07CA214839 · NCI · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI ROJEWSKI, ALANA · 2017 to 2021
$911k
Novel Treatment to Enhance Smoking Cessation before Cancer SurgeryR21CA181569 · NCI · YALE UNIVERSITY · PI TOLL, BENJAMIN ANDREW · 2014 to 2015
$438k
NCATS NIH HHS UL1 TR001863NCI NIH HHS K07 CA214839NCI NIH HHS R01 CA225697NCI NIH HHS R21 CA181569NHLBI NIH HHS T32 HL144470NIAMS NIH HHS K24 AR060297
6 · The paper itself

Abstract

introductionContingency management (CM) interventions deliver monetary reinforcers contingent upon biochemically verified abstinence from smoking. CM has been found to be effective, however, individual participant, analyses are warranted to further elucidate how individual-level behavior patterns vary during the intervention period, both within and across treatment groups. AIMS AND

methodsThis is a secondary analysis of a randomized controlled pilot trial of presurgical cancer patients who smoke (RCT N = 40). All participants were current everyday smokers and were enrolled in cessation counseling, offered nicotine replacement therapy, and submitted breath CO testing 3 times per week for 2-5 weeks. Participants randomized to CM received monetary reinforcers for breath CO ≤6 ppm on an escalating schedule of reinforcement with a reset for positive samples. Sufficient breath CO data exist for 28 participants (CM = 14; monitoring only [MO] = 14). Effect size was calculated for differences in negative CO tests. Time to first negative test was tested using survival analysis. Fisher's exact test was used to assess relapse.

resultsThe CM group achieved abstinence more quickly (p < .05), had a lower percentage of positive tests (h = 0.80), and experienced fewer lapses following abstinence (p = .00). While 11 of 14 participants in the CM group achieved and sustained abstinence by their third breath test, this was only true for 2 of the 14 MO participants.

conclusionsThose in CM achieved abstinence quicker and with fewer lapses than those engaged in MO speaking to the efficacy of the schedule of financial reinforcement. This is particularly important within presurgical populations given the potential benefits to postoperative cardiovascular and wound infection risk. IMPLICATIONS: While the efficacy of CM as an intervention is well established, this secondary analysis provides insight into the individual behavior patterns underlying successful abstinence. Those assigned to CM were not only more likely to achieve abstinence, but did so more quickly and with fewer instances of relapse. This is of particular importance to those scheduled for surgery where achieving abstinence as early as possible impacts on the risk of postoperative complications. CM interventions may be particularly well suited for critical windows in which timely and sustained abstinence is advantageous.

Indexed as

NeoplasmsSmoking CessationCarbon MonoxideHumansMotivationRecurrenceTobacco Use Cessation DevicesCarbon Monoxide

Identifiers

PMID37156634
PMCPMC10439489
OpenAlexW4375851372

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.